These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23951129)

  • 1. Pyrosequencing to identify homogeneous phenomenon when using recipients/donors with different CYP3A5*3 genotypes in living donor liver transplantation.
    Chiu KW; Nakano T; Chen KD; Lai CY; Hsu LW; Chiu HC; Huang CY; Cheng YF; Goto S; Chen CL
    PLoS One; 2013; 8(8):e71314. PubMed ID: 23951129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation.
    Chiu KW; Nakano T; Chen KD; Hsu LW; Lai CY; Chiu HC; Huang CY; Cheng YF; Goto S; Chen CL
    World J Hepatol; 2013 Nov; 5(11):642-8. PubMed ID: 24303093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis.
    Chiu KW; Nakano T; Chen KD; Hu TH; Lin CC; Hsu LW; Chen CL; Goto S
    Biomed Res Int; 2018; 2018():1826140. PubMed ID: 29686997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients.
    Mizuno S; Nakatani K; Muraki Y; Tanemura A; Azumi Y; Kuriyama N; Ohsawa I; Kishiwada M; Usui M; Sakurai H; Tabata M; Okuda M; Nobori T; Isaji S
    Ann Transplant; 2013 Jul; 18():349-57. PubMed ID: 23845965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
    Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation.
    Kato H; Usui M; Muraki Y; Tanemura A; Murata Y; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Okuda M; Nakatani K; Isaji S
    Transplant Proc; 2016 May; 48(4):1087-94. PubMed ID: 27320564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.
    Ji E; Choi L; Suh KS; Cho JY; Han N; Oh JM
    Transplantation; 2012 Oct; 94(8):866-72. PubMed ID: 22992768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism.
    Wan P; Hou Y; Qiu B; Feng M; Yang T; Luo Y; Xia L; Chen X; Zhang J; Xue F; Xia Q
    Biomed Res Int; 2022; 2022():7647754. PubMed ID: 36349313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients.
    Muraki Y; Usui M; Isaji S; Mizuno S; Nakatani K; Yamada T; Iwamoto T; Uemoto S; Nobori T; Okuda M
    Ann Transplant; 2011; 16(4):55-62. PubMed ID: 22210422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Subclinical Low Serum 25(OH)D in Donors and Fatty Liver Disease in Recipients after Living Donor Liver Transplantation.
    Chiu KW; Nakano T; Hu TH; Chen KD; Hsu LW; Eng HL; Cheng YF; Goto S; Chen CL
    Biomed Res Int; 2018; 2018():4508085. PubMed ID: 29750155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.
    Uesugi M; Masuda S; Katsura T; Oike F; Takada Y; Inui K
    Pharmacogenet Genomics; 2006 Feb; 16(2):119-27. PubMed ID: 16424824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms.
    Miyata Y; Akamatsu N; Sugawara Y; Kaneko J; Yamamoto T; Suzuki H; Arita J; Sakamoto Y; Hasegawa K; Tamura S; Kokudo N
    Ann Transplant; 2016 Aug; 21():491-9. PubMed ID: 27503662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
    Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
    Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.
    Rojas LE; Herrero MJ; Bosó V; García-Eliz M; Poveda JL; Librero J; Aliño SF
    Pharmacogenet Genomics; 2013 Oct; 23(10):509-17. PubMed ID: 23873120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
    Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.
    Liu J; Ouyang Y; Chen D; Yao B; Lin D; Li Z; Zang Y; Liu H; Fu X
    Int Immunopharmacol; 2018 Apr; 57():18-24. PubMed ID: 29454235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
    Buendia JA; Bramuglia G; Staatz CE
    Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.